NeurologyLive

12/26/2025

In a new guest article at NeurologyLive®, Danielle Andrade, MD, MSc, FRCPC, CSCN (EEG), professor of medicine at the University of Toronto, explored the evolving landscape of developmental and epileptic encephalopathies in adults.

To learn more, check out the article on our site here: https://hubs.li/Q03YYtf20

12/26/2025

🧠🎮 Ready to challenge your brain?
This week’s NeurologyLive® Brain Games focuses on neuromodulation for Parkinson disease—from DBS targets to adaptive systems. Try the 3-question quiz and share your results!

Test your knowledge here 👉 https://hubs.li/Q03YXCfw0

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!

12/25/2025

🧠 Phase 2 MS Trial Update

📌 Continuem’s remyelinating candidate PIPE-307 did not meet its primary endpoint in the VISTA trial for relapsing-remitting multiple sclerosis, though the therapy was found to be safe and well tolerated.

The placebo-controlled study evaluated PIPE-307’s effect on remyelination using binocular low contrast letter acuity. Despite the setback, Continuem plans to further analyze exploratory endpoints and publish the data, reinforcing its commitment to developing novel therapies for inflammatory and fibrotic diseases.

👉 Read more on what these findings mean for remyelination research in MS: https://hubs.li/Q03YZNvP0

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

12/25/2025

🧠✨ In 2025, key trends like artificial intelligence, gene therapy, personalized treatment, neuroplasticity, and genetics are transforming how neurologic diseases are diagnosed and treated. These innovations are helping clinicians move beyond one-size-fits-all care toward smarter, more individualized approaches.

📖 Dive into the full story: What’s All the Buzz? Trending Topics and Phrases of Neurology in 2025 👉 https://hubs.li/Q03YZPMh0

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

12/25/2025

🧠🤖 Introducing Frontlines with Frontera
Hosted by Jennifer Frontera, MD, this new NeurologyLive® podcast dives into complex, real-world challenges in neurocritical care and acute neurology.

In the debut episode, Dr. Frontera is joined by Sahar Zafar, MD, to discuss how AI—leveraging EEG, EHR data, and causal modeling—may improve seizure management, prognostication, and clinical trial design in the neuro ICU.

Listen to episode 1️⃣ here:

Frontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you an exclusive interview with Sahar Zafar, MD, MBBS. [LISTEN TIME: 30 minutes]

12/24/2025

🧪🧠 Phase 1b update: GT-02287 reduced CSF GluSph in patients with Parkinson disease, providing early evidence of CNS GCase target engagement.

GluSph is associated with α-synuclein aggregation, mitochondrial impairment, and neuronal stress—making this an encouraging biomarker signal for lysosomal pathway–based disease modification.

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

12/24/2025

📉 MS Pipeline Update: The phase 2 VISTA trial of PIPE-307, an investigational M1 receptor antagonist for RRMS, failed to meet its primary endpoint assessing remyelination via low-contrast letter acuity.

While the primary outcome was not achieved, Continuem plans to further analyze exploratory endpoints and present the data in a peer-reviewed forum—potentially informing future remyelination strategies.

Our coverage:

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

12/24/2025

This season, we’re thankful for the neurology community’s dedication to advancing care and research. Wishing you a peaceful holiday season and continued success in the year ahead. Happy holidays. 🧠✨

12/24/2025

Precision therapies for DEEs are advancing—but where do adults fit?
In this new feature, Danielle Andrade, MD, examines diagnostic gaps, evolving adult phenotypes, and why gene-specific diagnoses matter for trial access and care. 🧠📘

Read her perspectives:

Explore the evolving landscape of developmental and epileptic encephalopathies in adults, highlighting precision therapies and the need for accurate diagnoses.

12/24/2025

📊 Neurology Buzzwords, Decoded: In 2025, terms like artificial intelligence, gene therapy, neuroplasticity, and personalized treatment dominated conversations across neurology—but they represent more than hype.

In this end-of-year feature, NeurologyLive® breaks down how these buzzwords reflect meaningful changes in research, diagnostics, and patient care. 🧠🔬
Explore the trends:

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

12/23/2025

🧠🧬 Promising early progress in ALS research

New Phase 1 data from the LUMINA trial show that AMX0114, an investigational antisense therapy targeting calpain-2 (CAPN2), demonstrated a favorable safety and tolerability profile in people living with ALS—with no treatment-related serious adverse events reported.

By targeting a key driver of motor neuron injury and axonal degeneration, AMX0114 could represent a new therapeutic direction for a disease with urgent unmet needs. Biomarker results are expected in 2026 as the study continues.

Read more to learn how this first-in-human trial is shaping the future of ALS treatment 👉 https://hubs.li/Q03YRz9n0

New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.

12/23/2025

🧠🔬 Encouraging progress in Parkinson’s disease research!

A new Phase 1b update shows that GT-02287, a brain-penetrant small molecule from Gain Therapeutics, reduced glucosylsphingosine (GluSph) in cerebrospinal fluid, signaling improved GCase activity and potential benefits for neuronal health.

With a favorable safety profile, strong target engagement, and GluSph emerging as a key biomarker, this research highlights a promising path forward for therapies targeting the GCase-lysosome pathway in Parkinson’s disease.

✨ Longer-term data from the ongoing extension study is on the way so stay tuned! Read more to explore the science and what’s next 👉 https://hubs.li/Q03YRmQl0

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.